Author: "Rongioletti, F" / Search Limiters: Available in Library Collection - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Rongioletti, F"' showing total 451 results

Start Over Author "Rongioletti, F" Search Limiters Available in Library Collection

451 results on '"Rongioletti, F"'

1. Arrhythmias and other cardiovascular diseases in young patients (<40 years) with moderate/severe atopic dermatitis: A multicentric study in northern Italy

Author: Paolino, G, Carugno, A, Frontera, A, Rongioletti, F, Malagoli, P, Foti, A, Brianti, P, Guida, S, Germiniasi, F, Bianchi, V, Raponi, F, Sena, P, Narcisi, A, Costanzo, A, Mercuri, S, Valenti, M, Bianchi, V G, Mercuri, S R, Paolino, G, Carugno, A, Frontera, A, Rongioletti, F, Malagoli, P, Foti, A, Brianti, P, Guida, S, Germiniasi, F, Bianchi, V, Raponi, F, Sena, P, Narcisi, A, Costanzo, A, Mercuri, S, Valenti, M, Bianchi, V G, and Mercuri, S R
Published: 2024

2. Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma

Author: Paolino, G, Carugno, A, Rongioletti, F, Ponzoni, M, Russo, V, Sena, P, Ardigò, M, Costanzo, A, Mercuri, S, Valenti, M, Mercuri, SR, Paolino, G, Carugno, A, Rongioletti, F, Ponzoni, M, Russo, V, Sena, P, Ardigò, M, Costanzo, A, Mercuri, S, Valenti, M, and Mercuri, SR
Abstract: The occurrence of bone marrow metastases (BMM) in melanoma patients is often underestimated, with only 7% detected during in-vivo staging procedures but rising to 45% in autopsy cases. This systematic review aims to shed light on the clinical and laboratory features of BMM in melanoma by analyzing 73 studies selected from 2 482 initially retrieved from PubMed, Embase, and Cochrane CENTRAL databases. Our findings reveal a slight male predominance, with a median age at BMM diagnosis of 56 years. Primary melanoma sites included the skin (52%), mucosa (8.8%), uvea (20.5%) and unidentified (19%). BMM was preceded by lymph node involvement in 36.5% of cases, whereas 63% showed no nodal metastases, with direct BMM occurring in 22.5% and metastases to other sites in 41%. Common BMM symptoms included pain (60.7%), anemia (80%), thrombocytopenia, leukoerythroblastosis, pancytopenia and leukopenia, while disseminated intravascular coagulation was detected in 11% of cases. In 23.6% of cases, BMM was amelanotic. The prognosis for BMM is grim, with a median survival of only 2 months. Conventional therapies for BMM remain largely ineffective, emphasizing the importance of considering bone marrow as a potential metastatic site in melanoma patients.
Published: 2024

3. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Author: Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., Peris, K., Chiricozzi, A, Di Nardo, L, Talamonti, M, Galluzzo, M, De Simone, C, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Antonelli, F, Ferrucci, S, Guarneri, F, Peris, K, Chiricozzi, A., Di Nardo, L., Talamonti, M., Galluzzo, M., De Simone, C., Fabbrocini, G., Marzano, A. V., Girolomoni, G., Offidani, A., Rossi, M. T., Bianchi, L., Cristaudo, A., Fierro, M. T., Stingeni, L., Pellacani, G., Argenziano, G., Patrizi, A., Pigatto, P., Romanelli, M., Savoia, P., Rubegni, P., Foti, C., Milanesi, N., Belloni Fortina, A., Bongiorno, M. R., Grieco, T., Di Nuzzo, S., Fargnoli, M. C., Carugno, A., Motolese, A., Rongioletti, F., Amerio, P., Balestri, R., Potenza, C., Micali, G., Patruno, C., Zalaudek, I., Lombardo, M., Feliciani, C., Antonelli, F., Ferrucci, S. M., Guarneri, F., and Peris, K.
Published: 2022

4. 'Your Skin Tells You' Campaign for Keratinocyte Cancers: When Individuals' Selection Makes the Difference

Author: Fargnoli, Maria Concetta, Antonetti, P., Atzori, L., Taddeucci, P., Di Stefani, Alessandro, Grandi, Vera, Lospalluti, L., Lacarrubba, F., Vaccari, Stefano, Amerio, P., Fabbrocini, G., Rossi, M., Campione, E., Caposiena Caro, R. D., Moscarella, E., Rongioletti, F., Pellegrini, C., Peris, Ketty, Discab, Fargnoli M. C., Di Stefani A., Grandi V., Vaccari S. (ORCID:0000-0001-9280-7626), Peris K. (ORCID:0000-0002-5237-0463), Fargnoli, Maria Concetta, Antonetti, P., Atzori, L., Taddeucci, P., Di Stefani, Alessandro, Grandi, Vera, Lospalluti, L., Lacarrubba, F., Vaccari, Stefano, Amerio, P., Fabbrocini, G., Rossi, M., Campione, E., Caposiena Caro, R. D., Moscarella, E., Rongioletti, F., Pellegrini, C., Peris, Ketty, Discab, Fargnoli M. C., Di Stefani A., Grandi V., Vaccari S. (ORCID:0000-0001-9280-7626), and Peris K. (ORCID:0000-0002-5237-0463)
Abstract: Background: Prevention campaigns for skin cancers have focused primarily on melanoma, and over time there has been increasing awareness of the need to select the population to be screened to maximize program effectiveness. Objectives: The objective of the study was to report the results of a free dermatological initiative, as part of an awareness campaign dedicated to keratinocyte cancers, targeting individuals pre-selected through a short questionnaire. Methods: One day of dermatological consultations was held at 15 dermato-oncology referral centers during May 22-June 30, 2021. For selection, individuals answered a telephone interview consisting of 7 yes/no questions on risk factors. Demographics, clinical characteristics of suspicious tumors, and histopathologic diagnosis of excised lesions were collected. Suspicion rate, detection rate, and positive predictive values (PPVs) for any skin cancer, basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and melanoma were calculated. Results: A total of 320 individuals (56.9% males; 43.1% females) with a median age of 69.6 (range 21-91) years qualified for the screening initiative. Overall, skin cancers and precancerous lesions were diagnosed in 65.9% of the patients. Suspicion rate was 28.7% for any skin cancer (92/320), 22.8% for BCC (73/320), 4.7% for cSCC (15/320), and 1.2% for melanoma (4/320). Detection rate was 23.4% for any skin cancer (PPV 93.7%), 18.1% for BCC (PPV 95.1%), 4.4% for cSCC (PPV 93.3%), and 0.9% for melanoma (PPV 75%). Conclusions: Selection of individuals at high risk is a cost-effective approach for early detection campaigns for keratinocyte cancers.
Published: 2023

5. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

Author: Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., Piras V., Chiricozzi, A, Talamonti, M, De Simone, C, Galluzzo, M, Gori, N, Fabbrocini, G, Marzano, A, Girolomoni, G, Offidani, A, Rossi, M, Bianchi, L, Cristaudo, A, Fierro, M, Stingeni, L, Pellacani, G, Argenziano, G, Patrizi, A, Pigatto, P, Romanelli, M, Savoia, P, Rubegni, P, Foti, C, Milanesi, N, Belloni Fortina, A, Bongiorno, M, Grieco, T, Di Nuzzo, S, Fargnoli, M, Carugno, A, Motolese, A, Rongioletti, F, Amerio, P, Balestri, R, Potenza, C, Micali, G, Patruno, C, Zalaudek, I, Lombardo, M, Feliciani, C, Di Nardo, L, Guarneri, F, Peris, K, Caldarola, G, Silvaggio, D, Dattola, A, Napolitano, M, Ferrucci, S, Dal Bello, G, Bianchelli, T, Rovati, C, Pigliacelli, F, Ortoncelli, M, Hansel, K, Calabrese, G, Loi, C, Iannone, M, Veronese, F, Romita, P, Tronconi, G, Caroppo, F, Tilotta, G, Sernicola, A, Esposito, M, Raponi, F, Gualdi, G, Rech, G, Musumeci, M, Nistico, S, Campitiello, A, Bonzano, L, Piras, V, Chiricozzi A., Talamonti M., De Simone C., Galluzzo M., Gori N., Fabbrocini G., Marzano A. V., Girolomoni G., Offidani A., Rossi M. T., Bianchi L., Cristaudo A., Fierro M. T., Stingeni L., Pellacani G., Argenziano G., Patrizi A., Pigatto P., Romanelli M., Savoia P., Rubegni P., Foti C., Milanesi N., Belloni Fortina A., Bongiorno M. R., Grieco T., Di Nuzzo S., Fargnoli M. C., Carugno A., Motolese A., Rongioletti F., Amerio P., Balestri R., Potenza C., Micali G., Patruno C., Zalaudek I., Lombardo M., Feliciani C., Di Nardo L., Guarneri F., Peris K., Caldarola G., Silvaggio D., Dattola A., Napolitano M., Ferrucci S. M., Dal Bello G., Bianchelli T., Rovati C., Pigliacelli F., Ortoncelli M., Hansel K., Calabrese G., Loi C., Iannone M., Veronese F., Romita P., Tronconi G., Caroppo F., Tilotta G., Sernicola A., Esposito M., Raponi F., Gualdi G., Rech G., Musumeci M. L., Nistico S. P., Campitiello A., Bonzano L., and Piras V.
Abstract: Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
Published: 2021

6. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study

Author: Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., and Peris, K.
Abstract: Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
Published: 2021

7. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author: Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Hansel, K., Fargnoli, M. C., Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, K., Costanzo, A., Malara, G., Pellacani, G., Romanelli, M., Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, I., Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, R., Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli, Mc, Esposito, M, Ferrucci, S, Girolomoni, G, Offidani, A, Patrizi, A, Peris, K, Costanzo, A, Malara, G, Pellacani, G, Romanelli, M, Amerio, P, Cristaudo, A, Flori, Ml, Motolese, A, Betto, P, Patruno, C, Pigatto, P, Sirna, R, Stinco, G, Zalaudek, I, Bianchi, L, Boccaletti, V, Cannavò, Sp, Cusano, F, Lembo, S, Mozzillo, R, Gallo, R, Potenza, C, Rongioletti, F, Tiberio, R, Grieco, T, Micali, G, Persechino, S, Pettinato, M, Pucci, S, Savi, E, Stingeni, L, Romano, A, Argenziano, G, and Dupilumab Italian National Access Program (Dup-INAP, group).
Subjects: Male, Dermatitis, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Quality of life, Monoclonal, 80 and over, Humanized, Aged, 80 and over, Real-life, Atopic dermatitis, Middle Aged, Atopic dermatiti, Dupilumab, humanities, Treatment Outcome, atopic dermatitis, dupilumab, real-life, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, atopic dermatiti, Adult, medicine.medical_specialty, Context (language use), Dermatology, Antibodies, Monoclonal, Humanized, Antibodies, Atopic, Dermatitis, Atopic, 03 medical and health sciences, Young Adult, Internal medicine, Severity of illness, medicine, Humans, Adverse effect, Aged, Retrospective Studies, 030203 arthritis & rheumatology, business.industry, Pruritus, Retrospective cohort study, medicine.disease, Quality of Life, business, Sleep
Abstract: Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.
Published: 2021

8. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author: Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., Zangrilli A., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Belloni Fortina, A, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Venturini, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nistico, S, Giustini, S, Carugno, A, Cannavo, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Balestri, R, Bernardini, N, Botti, E, Burlando, M, Caldarola, G, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, M, Fidanza, R, Foti, C, Gambini, D, Gambardella, A, Girolomoni, G, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, M, Patrizi, A, Pellacani, G, Piaserico, S, Richetta, A, Rosi, E, Rossi, M, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Vezzoni, R, Zangrilli, A, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A. V., Potenza C., Conti A., Parodi A., Belloni Fortina A., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Venturini M., Bongiorno M. R., Feliciani C., Rubegni P., Amerio P., Fargnoli M. C., Pigatto P., Savoia P., Nistico S. P., Giustini S., Carugno A., Cannavo S. P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., Peris K., Balestri R., Bernardini N., Botti E., Burlando M., Caldarola G., Cattaneo A., Dapavo P., Dastoli S., De Simone C., Di Nuzzo S., Diotallevi F., Fierro M. T., Fidanza R., Foti C., Gambini D. M., Gambardella A., Girolomoni G., Guarneri C., Gualdi G., Hansel K., Megna M., Mugheddu C., Musumeci M. L., Patrizi A., Pellacani G., Piaserico S., Richetta A. G., Rosi E., Rossi M. T., Sacchelli L., Tiberio R., Tilotta G., Trovato E., Vezzoni R., and Zangrilli A.
Published: 2020

9. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions induced by Hydroxychloroquine in a woman with coronavirus disease 2019 (COVID-19)

Author: Robustelli Test, E, Vezzoli, P, Carugno, A, Raponi, F, Gianatti, A, Rongioletti, F, Sena, P, Robustelli Test, E., Vezzoli, P., Carugno, A., Raponi, F., Gianatti, A., Rongioletti, F., Sena, P., Robustelli Test, E, Vezzoli, P, Carugno, A, Raponi, F, Gianatti, A, Rongioletti, F, Sena, P, Robustelli Test, E., Vezzoli, P., Carugno, A., Raponi, F., Gianatti, A., Rongioletti, F., and Sena, P.
Published: 2020

10. Dupilumab in atopic dermatitis: predictors of treatment outcome and time to response

Author: Nettis, E., Ferrucci, S. M., Pellacani, G., Di Leo, E., Argenziano, G., Foti, C., Rongioletti, F., Patruno, C., Ortoncelli, M., Macchia, L., Tavecchio, S., Bonzano, L., Di Bona, D., Calabrese, G., Fabbrocini, G., Romita, P, Piras, V, Bennardo, L, Ribero, S, Napolitano, M, Bilancia, M, Detoraki, A, Nettis, E., Ferrucci, S. M., Pellacani, G., Di Leo, E., Argenziano, G., Foti, C., Rongioletti, F., Patruno, C., Ortoncelli, M., Macchia, L., Tavecchio, S., Bonzano, L., Di Bona, D., Calabrese, G., Fabbrocini, G., Romita, P, Piras, V, Bennardo, L, Ribero, S, Napolitano, M, Bilancia, M, and Detoraki, A
Subjects: medicine.medical_specialty, business.industry, Treatment outcome, MEDLINE, Eczema, Patient characteristics, Dermatology, Atopic dermatitis, medicine.disease, Antibodies, Monoclonal, Humanized, Dupilumab, Severity of Illness Index, Dermatitis, Atopic, Infectious Diseases, Treatment Outcome, Medicine, Humans, business, Human
Abstract: Recently, dupilumab, an anti-IL-4Rα antibody, has become available for the treatment of moderate-to-severe atopic dermatitis (AD).1-4 Baseline patient characteristics that can be used as predictors of response to dupilumab treatment in AD patients have not yet been identified.
Published: 2021

11. Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w)

Author: Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, Anna Maria, Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Borghi A., Gori N., Gallo R., Tonini G., Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, Anna Maria, Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Borghi A., Gori N., Gallo R., and Tonini G.
Abstract: In this article the author group details were incorrectly displayed with Collaborators included in the main author group. M. Talamonti (Dermatology Unit, Policlinico Tor Vergata Rome, University of Rome Tor Vergata, Rome, Italy). The original article has been corrected.
Published: 2022

12. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study

Author: Pellacani, G., Bigi, L., Parodi, A., Burlando, M., Lanna, C., Campione, E., Rongioletti, F., Mugheddu, C., Malara, G., Moretti, G., Stingeni, L., Hansel, K., Micali, G., Naldi, L., Pirro, Federico, Peris, Ketty, Pirro F., Peris K. (ORCID:0000-0002-5237-0463), Pellacani, G., Bigi, L., Parodi, A., Burlando, M., Lanna, C., Campione, E., Rongioletti, F., Mugheddu, C., Malara, G., Moretti, G., Stingeni, L., Hansel, K., Micali, G., Naldi, L., Pirro, Federico, Peris, Ketty, Pirro F., and Peris K. (ORCID:0000-0002-5237-0463)
Abstract: This open-label multicentre trial evaluated the efficacy and safety of oral dimethyl fumarate (DMF) in patients with moderate-to-severe plaque psoriasis in real-life clinical practice over 52 weeks. Disease severity and improvement were assessed using the psoriasis area severity index (PASI), body surface area (BSA) affected, and Physician Global Assessment (PGA). Quality of life (QoL) was assessed using the Dermatology Life Quality Index (DLQI) questionnaire. The visual analogue scale (VAS) was used to quantify pruritus and measure treatment satisfaction. A total of 141 patients were included, being 66.7% male, aged 49.1 ± 14.7 years and with disease duration of 16 ± 12.1 years. After 52 weeks, mean PASI decreased from 15.9 ± 6.8 to 1.5 ± 2 and 87.7%, 56.9% and 24.6% of patients achieved PASI 75/90/100 response, respectively. BSA decreased from 26.5 ± 14.8% to 2.7 ± 3.5% at 52 weeks, and 81.5% of patients had a PGA 0-1. DLQI scores decreased from 9.4 ± 6.4 to 2.1 ± 3.3, and VAS of pruritus decreased from 53 ± 28.4 to 19.1 ± 26.2 at Week 52. VAS for treatment satisfaction was 79.4 ± 29.4 at Week 52. A total of 34.2% of patients had an AE leading to permanent discontinuation. These findings show that DMF can significantly improve indices of disease severity, pruritus and QoL, with high levels of patient satisfaction and similar safety profile to other fumarates.
Published: 2022

13. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis

Author: Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Gisondi, P., Fargnoli, M. C., Amerio, P., Argenziano, G., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Conti, A., Corazza, M., Costanzo, A., Dapavo, P., De Simone, Clara, Fabbrocini, G., Feliciani, C., Foti, C., Girolomoni, G., Guarneri, C., Marzano, A. V., Micali, G., Offidani, A., Parodi, A., Pellacani, G., Piaserico, S., Prignano, F., Romanelli, M., Rongioletti, F., Rubegni, P., Stinco, G., Stingeni, L., Tomasini, C. F., Venturini, M., Peris, Ketty, Calzavara-Pinton, P., Chiricozzi A. (ORCID:0000-0002-6739-0387), DE Simone C. (ORCID:0000-0002-0898-0045), and Peris K. (ORCID:0000-0002-5237-0463)
Abstract: SIDeMaST (Società Italiana di Dermatologia Medica, Chirurgica, Estetica e delle Malattie Sessualmente Trasmesse) contributed to the development of the present guideline on the systemic treatment of chronic plaque psoriasis. With the permission of EuroGuiDerm, SIDeMaST adapted the guideline to the Italian healthcare context to supply a reliable and affordable tool to Italian physicians who take care of patients affected by moderate to severe plaque psoriasis. The content of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline, suggestions for disease severity grading and treatment goals. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs including acitretin, cyclosporine, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab. Moreover, the guideline provides guidance for specific clinical situations such as patient with concomitant psoriatic arthritis, inflammatory bowel disease, a history of malignancies, a history of depression, diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or those with childbearing potential. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.
Published: 2022

14. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Author: Nettis, E, primary, Ferrucci, SM, additional, Ortoncelli, M, additional, Pellacani, G, additional, Foti, C, additional, Di Leo, E, additional, Patruno, C, additional, Rongioletti, F, additional, Argenziano, G, additional, Macchia, L, additional, Tavecchio, S, additional, Napolitano, M, additional, Ribero, S, additional, Bonzano, L, additional, Romita, P, additional, Di Bona, D, additional, Nisticò, SP, additional, Piras, V, additional, Calabrese, G, additional, Detoraki, C, additional, Carbonara, M, additional, and Fabbrocini, G, additional
Published: 2022
Full Text: View/download PDF

15. Potpourri from A to Z: I. Clin Dermatol. 2021 Nov-Dec;39(6):931-933. doi: 10.1016/j.clindermatol.2021.07.013. Epub 2021 Aug 8. PMID: 34920832

Author: Hoenig LJ, Rongioletti F, Petronic-Rosic V., Hoenig, Lj, Rongioletti, F, and Petronic-Rosic, V.
Published: 2021

16. SarS-CoV-2 vaccines and biological treatments: Dermatological perspectives

Author: Stingeni L., Bianchi L., Peris K., Fabbrocini G., Micali G., Calzavara-Pinton P., Tramontana M., Hansel K., Rongioletti F., on behalf of SIDemaSt, Stingeni, L., Bianchi, L., Peris, K., Fabbrocini, G., Micali, G., Calzavara-Pinton, P., Tramontana, M., Hansel, K., Stingeni L., Bianchi L., Peris K., Fabbrocini G., Micali G., Calzavara-Pinton P., Tramontana M., Hansel K., Piraccini B.M., Rongioletti, F., and on behalf of, Sidemast
Subjects: 2019-20 coronavirus outbreak, Settore MED/35 - Malattie Cutanee e Veneree, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), business.industry, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Skin Disease, fungi, COVID-19, Dermatology, Virology, Skin Diseases, body regions, Biological Therapy, Infectious Diseases, Medicine, Humans, biological treatment, business, skin and connective tissue diseases, Human
Abstract: More than 60 SARS-CoV-2 vaccine candidates are currently in clinical trials and more than 170 vaccines are in different stages of preclinical evaluation worldwide
Published: 2021

17. Clinicopathologic features between different viral epidemic outbreaks involving the skin: Dermatologic involvement in viral outbreaks

Author: Atzori L., Ferreli C., Mateeva V., Vassileva S., Rongioletti F., Atzori, L., Ferreli, C., Mateeva, V., Vassileva, S., and Rongioletti, F.
Subjects: SARS-CoV-2, Humans, COVID-19, Pandemics, Disease Outbreaks, Skin
Abstract: The current coronavirus disease 2019 pandemic has exceeded any epidemiologic prevision, but increasing information suggests some analogies with the major viral outbreaks of the last century. A general warning has been issued on the possibility that coinfections can make differential diagnosis and treatment difficult, especially in tropical countries. Some reports have pointed out that the presence of high Dengue antibodies can give a false-negative result for severe acute respiratory syndrome coronavirus 2. Mucocutaneous manifestations are very frequent, with an apparent overlap among different pathogens. A strong clinicopathologic correlation, however, may provide some clues to address the differential. Waiting for laboratory and instrumental results, the timing and distribution of skin lesions is often pathognomonic. Histopathologic findings characterize certain reaction patterns and provide insights on pathogenetic mechanisms. Unfortunately, skin assessments, especially invasive exams such as biopsy, are less important in severely ill patients. A literature review was performed to collect information from other epidemics to counteract what has become the most frightening disease of our time.
Published: 2021

18. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study

Author: Patruno, C., Fabbrocini, G., Longo, G., Argenziano, G., Ferrucci, S. M., Stingeni, L., Peris, K., Ortoncelli, M., Offidani, A., Amoruso, G. F., Talamonti, M., Girolomoni, G., Grieco, T., Iannone, M., Nettis, E., Foti, C., Rongioletti, F., Corazza, M., Veneri, M. D., Napolitano, M., Angileri, L., Bianchelli, T., Borghi, A., Calabrese, G., Chello, C., Dal Bello, G., Dastoli, S., Ferrillo, M., Galluzzo, M., Gori, N., Hansel, K., Macchia, L., Piras, V., Provenzano, E., Ribero, S., Romanelli, M., Romita, P., Patruno, C., Fabbrocini, G., Longo, G., Argenziano, G., Ferrucci, S. M., Stingeni, L., Peris, K., Ortoncelli, M., Offidani, A., Amoruso, G. F., Talamonti, M., Girolomoni, G., Grieco, T., Iannone, M., Nettis, E., Foti, C., Rongioletti, F., Corazza, M., Veneri, M. D., Napolitano, M., Angileri, L., Bianchelli, T., Borghi, A., Calabrese, G., Chello, C., Dal Bello, G., Dastoli, S., Ferrillo, M., Galluzzo, M., Gori, N., Hansel, K., Macchia, L., Piras, V., Provenzano, E., Ribero, S., Romanelli, M., and Romita, P.
Subjects: Male, medicine.medical_specialty, Time Factors, Injections, Subcutaneous, Socio-culturale, Dermatology, Antibodies, Monoclonal, Humanized, Eczema Area and Severity Index, elderly, Severity of Illness Index, Drug Administration Schedule, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Pharmacotherapy, Settore MED/35, Internal medicine, atopic dermatitis, dupilumab, medicine, Humans, Adverse effect, Contraindication, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Pruritus, Age Factors, General Medicine, Atopic dermatitis, Dermatology Life Quality Index, medicine.disease, Conjunctivitis, Dupilumab, Injection Site Reaction, Treatment Outcome, Quality of Life, Observational study, Female, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business
Abstract: Objective: The objective of this study was to assess the effectiveness and safety of dupilumab in treating elderly patients with atopic dermatitis from baseline to 52 weeks. Methods: A retrospective observational real-life study was conducted in a group of elderly patients with severe atopic dermatitis treated with dupilumab for 52 weeks. Inclusion criteria were: age ≥ 65 years; diagnosis of atopic dermatitis made by an expert dermatologist; Eczema Area and Severity Index ≥ 24; and a contraindication, side effects, or failure to respond to cyclosporine. The primary outcome was the mean percentage reduction in the Eczema Area and Severity Index score from baseline to week 52. Secondary measures includedthe mean percentage reduction in the Pruritus and Sleep Numerical Rating Scales and the Dermatology Life Quality Index, and the types and rates of adverse events from baseline to week 52. Results: One hundred and five patients were eligible for the study. Flexural dermatitis was the most frequent clinical phenotype (63.8%). The coexistence of more than one clinical phenotype was found in 70/105 (66.6%) patients. We observed a reduction in all disease severity scores from baseline to week 52 (p < 0.001). Adverse events were recorded in 30/105 (28.6%) patients, with conjunctivitis and injection-site reaction the most frequent. Conclusions: In this study, dupilumab is an effective and safe treatment for the long-term management of atopic dermatitis in patients aged over 65 years.
Published: 2021

19. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP)

Author: Calzavara-Pinton P., Fortina A. B., Bonamonte D., Marseglia G. L., Del Giudice M. M., Musarra A., Nettis E., Neri I., Patruno C., Stingeni L., Peris K., Rongioletti F., on behalf of raDar group, Calzavara-Pinton, P., Fortina, A. B., Bonamonte, D., Marseglia, G. L., Del Giudice, M. M., Musarra, A., Nettis, E., Neri, I., Patruno, C., Stingeni, L., Peris, K., Rongioletti, F., and on behalf of raDar, Group
Subjects: Adult, therapy, Consensus, Adolescent, Dermatitis, Dermatology, Dupilumab, Atopic, Hospitals, Asthma, Dermatitis, Atopic, Infectious Diseases, Allergists, Italy, Venereology, Diagnosis, Quality of Life, Humans, Therapy, Public Health, Child, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Dermatologists, Atopic dermatitis
Abstract: Atopic dermatitis (AD) is a chronic inflammatory disease with increasing global incidence, which has a multifactorial pathogenesis and a variable expressivity. Clinical features of AD are different in adults compared to children, but it is well recognized the substantial impact of the disease on patients' quality of life at any age. Indeed, little is known about AD in adolescence, a period of life generally associated with high psychological burden and vulnerability to depression. Guidelines for the management of AD are available for both children and adults but specific guidelines for the diagnosis and treatment of AD in adolescents are lacking. Seven Italian scientific societies of dermatologists, allergists, and pediatric allergists joined in a specific meeting to provide practical guidance for the diagnosis and management of moderate-to-severe adolescent AD suitable for the Italian clinical practice. Through a modified Delphi procedure, consensus was reached by 59 Italian experts in the management of AD on 20 statements covering five areas of interest about adolescent AD, including disease complexity, burden and social impact, diagnosis and defini tion of severity, current treatments, and new biologic therapies. This paper reports recommendations for the diagnosis and management of AD specifically in adolescents, pointing out some peculiar clinical features and focusing on the choice of medications. Dupilumab, the first biologic approved for the treatment of adolescents with AD, represents a useful treatment option due to its efficacy and reassuring safety profile.
Published: 2021

20. Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis. The LION real-life multicenter prospective observational cohort study

Author: Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., Pigatto, P., Cruciani, G., De Simone, C., Caldarola, G., Grimaldi, M., Anedda, J., Bernardini, N., Marchesiello, A., Franchi, C., Dattola, A., Botti, E., Zedde, P., Cammarata, E., Radi, G., Rosi, E., De Rosa, A., Esposito, M., Marietti, R., Lupi, F., Grazzini, M., Domenico, D. M., Brusasco, M., Gai, F., Campanati, A., Atzori, L., Potenza, C., Damiani, G., Bianchi, L., Corazza, M., Tiberio, R., Prignano, F., Argenziano, G., Fargnoli, M. C., Stingeni, L., Mazzotta, A., De Pita, O., Mazzatenta, C., Feliciani, C., Donini, M., Offidani, A., Peris, K., Rongioletti, F., and on behalf of the LION study group—Italian Participating, Centers
Subjects: Adult, Male, medicine.medical_specialty, Dermatologic Agent, psoriasis, therapy-topical, Betamethasone dipropionate, Dermatology, Betamethasone, NO, chemistry.chemical_compound, Patient satisfaction, Calcitriol, Psoriasis, Internal medicine, Drug Combination, medicine, Humans, Prospective Studies, Prospective cohort study, Calcipotriol, psoriasi, therapy-topical, business.industry, psoriasis, General Medicine, Middle Aged, medicine.disease, Prospective Studie, Drug Combinations, Treatment Outcome, chemistry, Patient Satisfaction, Cohort, Observational study, Dermatologic Agents, Settore MED/35 - MALATTIE CUTANEE E VENEREE, business, Cohort study, medicine.drug, Human
Abstract: Topical treatment is the mainstay for mild or moderate psoriasis, but patients are generally little satisfied. Calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam has shown to improve signs and symptoms in plaque psoriasis patients. This study assessed patient's satisfaction with Cal/BD foam in a real-life Italian dermatological clinical practice. A multicenter, 4-week observational prospective cohort study enrolled, in 17 Italian dermatology clinics, adult patients with plaque psoriasis on the body and/or scalp. Treatment satisfaction was assessed by 9-item Treatment Satisfaction Questionnaire for Medication (TSQM-9), preference over previous treatments by Patient Preference Questionnaire (PPQ), and change in disease state by Psoriasis Area Severity Index (PASI). Overall 256 patients were eligible, with a mean (SD) age of 55.6 (15.4) years, 59.4% were males. Psoriasis severity was mild in 52.0% of patients, moderate in 43.3%, and severe in 4.7%. Scalp involvement was present in 36.7% of patients. Previous antipsoriatic treatments had been received by 80.5% of patients. TSQM-9 median (25th-75th percentile) scores were 83.3 (66.7-88.9) for effectiveness, 77.8 (66.7-88.9) for convenience, and 78.6 (64.3-92.9) for global satisfaction. Mean (SD) PASI value decreased from 7.3 (4.8) to 2.1 (2.7) after 4 weeks. More than 90% of patients previously treated for psoriasis evaluated the Cal/BD foam more effective, easier to use and better tolerated compared to previous topical treatments at PPQ. This observational study provides real-life evidence of a high level of satisfaction with effectiveness and convenience of the Cal/BD foam in a cohort of plaque psoriasis patients, with an objective improvement in PASI.
Published: 2021

21. Fatal hyalohyphomycosis with cutaneous involvement caused by purpureocillium lilacinum in an immunocompromised patient with bullous pemphigoid

Author: Corbeddu M., Ferreli C., Cappai R., Ferraguti P., Atzori L., Pilloni L., Rongioletti F., Corbeddu, M., Ferreli, C., Cappai, R., Ferraguti, P., Atzori, L., Pilloni, L., and Rongioletti, F.
Subjects: Male, Hyalohyphomycosis, Immunocompromised Host, Hypocreales, Pemphigoid, Bullous, Humans, Paecilomyces
Abstract: Emergent pathogen as Purpureocillium lilacinum are becoming cause of morbidity and mortality in our population, especially in immunocompromised patients. We describe a case of hyalohyphomycosis in a diabetic man under systemic steroid treatment for a bullous pemphigoid. Treatment with different antimycotic drugs were ineffective and infection spread diffusely, leading to deterioration of general conditions and ultimately death. The aim of this article is to increase awareness of clinicians about this uncommon, but frequently fatal refractory mycotic infection.
Published: 2021

22. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author: Patruno C., Napolitano M., Argenziano G., Peris K., Ortoncelli M., Girolomoni G., Offidani A., Ferrucci S. M., Amoruso G. F., Rossi M., Stingeni L., Malara G., Grieco T., Foti C., Gattoni M., Loi C., Iannone M., Talamonti M., Stinco G., Rongioletti F., Pigatto P. D., Cristaudo A., Nettis E., Corazza M., Guarneri F., Amerio P., Esposito M., Belloni Fortina A., Potenza C., Fabbrocini G., Angileri L., Bianchelli T., Borghi A., Buligan C., Calabrese G., Calzavara Pinton P., Caroppo F., Chello C., Dal Bello G., Damiani G., Fargnoli M. C., Ferrillo M., Galluzzo M., Gori N., Gualdi G., Hansel K., Macchia L., Mariano M., Nistico S. P., Pertusi G., Piras V., Provenzano E., Ravaioli G. M., Ribero S., Romanelli M., Romita P., Tolino E., Trifiro C., Patruno, C., Napolitano, M., Argenziano, G., Peris, K., Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, M., Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, M. C., Ferrillo, M., Galluzzo, M., Gori, N., Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, E., Ravaioli, G. M., Ribero, S., Romanelli, M., Romita, P., Tolino, E., and Trifiro, C.
Subjects: Adult, medicine.medical_specialty, Adolescent, multicentre, Treatment outcome, Eczema, Socio-culturale, Dermatitis, Dupilumab, atopic dermatitis, multicentre, real-life study, Dermatology, Antibodies, Monoclonal, Humanized, elderly, Severity of Illness Index, Antibodies, Atopic, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, Settore MED/35, 0302 clinical medicine, Internal medicine, Aged, Humans, Middle Aged, Retrospective Studies, Monoclonal, Medicine, 030212 general & internal medicine, Adverse effect, Humanized, atopic dermatitis, business.industry, dupilumab, Atopic dermatitis, medicine.disease, humanities, Safety profile, Infectious Diseases, Observational study, real-life study, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Life study, business, Prurigo nodularis
Abstract: Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.
Published: 2020

23. SARS‐CoV, Mers‐CoV and COVID‐19: what differences from a dermatological viewpoint?

Author: Rongioletti, F. and Rongioletti, F.
Subjects: 2019-20 coronavirus outbreak, Coronavirus disease 2019 (COVID-19), Middle East respiratory syndrome coronavirus, viruses, Pneumonia, Viral, Severe disease, Dermatology, medicine.disease_cause, Letter to Editor, Skin Diseases, skin manifestations, Betacoronavirus, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, MERS, Pandemic, medicine, Humans, 030212 general & internal medicine, skin and connective tissue diseases, Pandemics, Coronavirus, SARS, Covid‐19, biology, SARS-CoV-2, business.industry, fungi, COVID-19, virus diseases, Outbreak, biology.organism_classification, Virology, respiratory tract diseases, Infectious Diseases, Severe acute respiratory syndrome-related coronavirus, Middle East Respiratory Syndrome Coronavirus, coronavirus outbreaks, Coronavirus Infections, business
Abstract: Over the past two decades, 3 zoonotic global coronavirus outbreaks have occurred: 1. SARS starting in 2002 in China due to SARS‐CoV; 2. MERS starting in 2012 in Saudi Arabia due to MERS‐CoV; 3. Covid‐19 due to SARS‐CoV‐2 starting in 2019 in Wuhan, China (1). Both beta‐coronaviruses, SARS‐CoV and MERS‐CoV caused a severe disease in most infected people.
Published: 2020

24. Hidradenitis suppurativa epidemiology. From the first Italian registry in 2009 to the most recent epidemiology updates - Italian Registry Hidradenitis Suppurativa project 2

Author: Bettoli, V., Cazzaniga, S., Scuderi, V., Zedde, P., Di Landro, A., Naldi, L., Cannavò, S., Fabbrocini, G., Marzano, A. V., Mazzanti, C., Offidani, A., Patrizi, A., Pellacani, G., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Bettoli, V., Cazzaniga, S., Scuderi, V., Zedde, P., Di Landro, A., Naldi, L., Cannavo, S., Fabbrocini, G., Marzano, A. V., Mazzanti, C., Offidani, A., Patrizi, A., Pellacani, G., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Bettoli V., Cazzaniga S., Scuderi V., Zedde P., Di Landro A., Naldi L., Cannavo S., Fabbrocini G., Marzano A.V., Mazzanti C., Offidani A., Patrizi A., Pellacani G., Pimpinelli N., Potenza C., Romanelli M., and Rongioletti F.
Subjects: Adult, Male, Registrie, medicine.medical_specialty, MEDLINE, Dermatology, Body Mass Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Age Distribution, Epidemiology, medicine, Prevalence, Humans, Hidradenitis suppurativa, Registries, Young adult, Age of Onset, Sex Distribution, business.industry, Incidence (epidemiology), Incidence, Smoking, hidradenitis suppurativa, medicine.disease, Infectious Diseases, Italy, 030220 oncology & carcinogenesis, Age distribution, Female, Age of onset, business, Body mass index, Demography, Human
Abstract: BACKGROUND The incidence of hidradenitis suppurativa (HS) is still not fully established with only a few studies reporting its estimates. Prevalence estimates range from 5:10 000 to 4:100. These extremely large variations could be explained by a combination of factors, including different selection procedures, different diagnostic criteria, and variations in the sex and age distribution of the examined samples. OBJECTIVES To analyze variations between two consecutive Italian Registries on HS. METHODS Data obtained from the second Italian Registry on HS, named 'Italian Registry Hidradenitis Suppurativa (IRHIS) Project 2', are compared to the previous first Italian registry on HS. RESULTS Data on 944 patients are reported. The more relevant aspects that characterize IRHIS 2 project, in comparison with the previous first Italian Registry on HS, are as follows: (i) the total number of patients, about fourfold higher; (ii) a more uniform national geographic distribution of the patient population; (iii) a larger number of dermatology units involved; (iv) a larger number of items considered in the data collection; (v) 6 years of difference between the onset of the two registries (2009-2013 vs. 2015-2019). Comparing data of the two registries, there are no statistically significant differences in terms of age at the time of the visit, gender, BMI, smoking habits, age at onset and age at first diagnosis by physician. Interestingly, the mean Sartorius score in the IRHIS project 2 (58.8) was significantly lower compared to the first Italian Registry (78.4). CONCLUSIONS The importance of the registries, at both national and international levels, in collecting useful real-life data is confirmed by these two Italian projects.
Published: 2019

25. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience

Author: Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba, F., Dini, V., Napolitano, M., Venturini, M., Caposiena Caro, D. R., Molinelli, E., Passoni, E., Monfrecola, G., Argenziano, G., Berti, E., Bianchi, L., Calzavara Pinton, P., Cannavo, S. P., Costanzo, A., Donini, M., Fabbrocini, G., Fierro, M. T., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Peris, K., Pimpinelli, N., Potenza, C., Romanelli, M., Rongioletti, F., Solivetti, F., Lacarrubba F., Dini V., Napolitano M., Venturini M., Caposiena Caro D.R., Molinelli E., Passoni E., Monfrecola G., Argenziano G., Berti E., Bianchi L., Calzavara Pinton P., Cannavo S.P., Costanzo A., Donini M., Fabbrocini G., Fierro M.T., Micali G., Offidani A., Parodi A., Patrizi A., Pellacani G., Peris K., Pimpinelli N., Potenza C., Romanelli M., Rongioletti F., and Solivetti F.
Subjects: Adult, Male, medicine.medical_specialty, Standard of care, Dermatology, Severity of Illness Index, 030207 dermatology & venereal diseases, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Disease severity, Retrospective Studie, Internal medicine, medicine, Humans, Hidradenitis suppurativa, Radiation treatment planning, Grading (tumors), Physical Examination, Retrospective Studies, Ultrasonography, Settore MED/35 - Malattie Cutanee e Veneree, business.industry, Ultrasound, Retrospective cohort study, Middle Aged, medicine.disease, Hidradenitis Suppurativa, Infectious Diseases, Ultrasound Working Group experience, 030220 oncology & carcinogenesis, Female, business, Human
Abstract: Background: Ultrasound (US) is a real-time non-invasive technique that has been demonstrated to support an early diagnosis and a more precise assessment of hidradenitis suppurativa (HS). Objectives: To compare the clinical and US evaluation of a series of HS patients. Methods: 434 HS patients (259 F, 175 M; mean age 33.82 ±13.31 years) observed across 19 Italian dermatology centres [members of the Italian Ultrasound Working Group (IUWG)] were enrolled in a retrospective study. Clinical staging was obtained by the Hidradenitis Suppurativa Physician's Global Assessment score (HS-PGA), while the ultrasonographic staging was determined by the US HS-PGA, based on the same scores as clinical HS-PGA but performed with the aid of US. Results: At the end of the study, the mean clinical and US HS-PGA scores were 2.70 and 2.92, respectively. Direct comparison of clinical and ultrasonographic assessment revealed that a higher proportion of patients was classified as having moderate and very severe disease by US. In particular, 117 patients (26.96%) had a worse classification by US HS-PGA compared to clinical assessment. Conclusion: Our findings confirm that the use of clinical grading only to assess HS severity may underestimate the real disease severity. US examination can be considered an essential non-invasive imaging tool available to dermatologists for a more accurate diagnosis, staging, treatment planning and monitoring of HS and should be included in the pathway to an optimal standard of care of HS.
Published: 2019

26. The Italian dermatologic community facing COVID-19 pandemic: Recommendation from the Italian society of dermatology and venereology

Author: Micali, G., Musumeci, M. L., Peris, Ketty, Pinton, P. C., Conti, A., Fabbrocini, G., Frascione, P., Pigatto, P., Piraccini, B. M., Rongioletti, F., Rubegni, P., Stingeni, L., Micali G, Musumeci ML, Peris K, Piraccini B.M., Board Members of the SIDeMaST., Micali, G., Musumeci, M. L., Peris, K., Pinton, P. C., Conti, A., Fabbrocini, G., Frascione, P., Pigatto, P., Piraccini, B. M., Rongioletti, F., Rubegni, P., and Stingeni, L.
Subjects: medicine.medical_specialty, 2019-20 coronavirus outbreak, Venereology, Infectious Disease Transmission, Patient-to-Professional, Coronavirus disease 2019 (COVID-19), COVID, hospital, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Infectious Disease Transmission, Pneumonia, Viral, Viral transmission, Sexually Transmitted Diseases, Dermatology, Betacoronavirus, COVID-19, Coronavirus Infections, Humans, Infection Control, Italy, Pandemics, Practice Guidelines as Topic, SARS-CoV-2, Skin Diseases, Patient-to-Professional, Pandemic, medicine, Viral, Sexually Transmitted Disease, Betacoronaviru, Coronavirus Infection, business.industry, Infectious disease transmission, Skin Disease, Pneumonia, Family medicine, business, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Human
Abstract: The “Società Italiana di Dermatologia medica, chirurgica, estetica e delle Malattie Sessualmente Trasmesse (SIDeMaST)” has timely developed an “emergency plan” by issuing a series of informative sheets also named “vademecum” addressed to both dermatologists and patients.
Published: 2020

27. Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study

Author: Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, A., Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Gori N., Gallo R., Tonini G., Campanati, A., Bianchelli, T., Gesuita, R., Foti, C., Malara, G., Micali, G., Amerio, P., Rongioletti, F., Corazza, M., Patrizi, A., Peris, Ketty, Pimpinelli, N., Parodi, A., Fargnoli, Maria Concetta, Cannavo, S. P., Pigatto, P., Pellacani, G., Ferrucci, S. M., Argenziano, G., Cusano, F., Fabbrocini, G., Stingeni, L., Potenza, M. C., Romanelli, Margherita, Bianchi, L., Offidani, A., Romita, P., Musumeci, M. L., Piras, V., Borghi, A., Loi, C., Gori, Niccolo', Prigano, F., Gallo, Rosanna, Esposito, M., Campitello, A., Bolzano, L., Tavecchio, S., Calabrese, G., Di Costanzo, L., Hansel, K., Skroza, N., Tolino, E., Tonini, Gerolamo, Talamonti, M., Peris K. (ORCID:0000-0002-5237-0463), Fargnoli M. C., Romanelli M., Gori N., Gallo R., and Tonini G.
Abstract: Adult atopic dermatitis (adult AD) is a systemic inflammatory disorder, whose relationship with immune-allergic and metabolic comorbidities is not well established yet. Moreover, treatment of mild-to-moderate and severe atopic dermatitis needs standardization among clinicians. The aim of this study was to evaluate the distribution of comorbidities, including metabolic abnormalities, rhinitis, conjunctivitis, asthma, alopecia and sleep disturbance, according to severity of adult AD, and describe treatments most commonly used by Italian dermatologists. Retrospective, observational, nationwide study of adult patients over a 2-year period was performed. Clinical and laboratory data were obtained through review of medical records of patients aged ≥ 18 years, followed in 23 Italian National reference centres for atopic dermatitis between September 2016 and September 2018. The main measurements evaluated were disease severity, atopic and metabolic comorbidities, treatment type and duration. Six-hundred and eighty-four adult patients with AD were included into the study. Atopic, but not metabolic conditions, except for hypertension, were significantly associated with having moderate-to-severe AD in young adult patients. Disease duration was significantly associated with disease severity. Oral corticosteroids and cyclosporine were the most widely used immunosuppressant. Our study seems confirm the close relationship between adult AD and other atopic conditions, further long-term cohort studies on patients affected by adult AD need to be performed to evaluate the complex relationship between adult AD disease severity and metabolic comorbidities.
Published: 2021

28. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

Author: Chiricozzi, Andrea, Costanzo, A., Fargnoli, M. C., Malagoli, P., Piaserico, S., Amerio, P., Argenziano, G., Balato, N., Bardazzi, F., Bianchi, L., Carrera, C. G., Conti, A., Dapavo, P., De Simone, Clara, Loconsole, F., Lo Schiavo, A., Malara, G., Musumeci, M. L., Parodi, A., Peris, Ketty, Prignano, F., Rongioletti, F., Talamonti, M., Potenza, C., Chiricozzi A. (ORCID:0000-0002-6739-0387), De Simone C. (ORCID:0000-0002-0898-0045), Peris K. (ORCID:0000-0002-5237-0463), Chiricozzi, Andrea, Costanzo, A., Fargnoli, M. C., Malagoli, P., Piaserico, S., Amerio, P., Argenziano, G., Balato, N., Bardazzi, F., Bianchi, L., Carrera, C. G., Conti, A., Dapavo, P., De Simone, Clara, Loconsole, F., Lo Schiavo, A., Malara, G., Musumeci, M. L., Parodi, A., Peris, Ketty, Prignano, F., Rongioletti, F., Talamonti, M., Potenza, C., Chiricozzi A. (ORCID:0000-0002-6739-0387), De Simone C. (ORCID:0000-0002-0898-0045), and Peris K. (ORCID:0000-0002-5237-0463)
Abstract: Guselkumab, a subcutaneously administered fully human IgG1lambda monoclonal antibody that selectively inhibits the p19 subunit of interleukin 23, is approved in both the USA and the EU for the treatment of adult patients with moderate-to-severe plaque psoriasis. The efficacy and safety of guselkumab were demonstrated in four randomized, double-blind, Phase III trials (VOYAGE 1 and 2, NAVIGATE, and ECLIPSE), which demonstrated high levels of clinical response over three years of continuous treatment, regardless of sex, age, body weight, and race, maintaining a favourable safety profile and long-term tolerability. Guselkumab was shown to be efficacious in patients with prior failure of other biologics, including adalimumab and ustekinumab, and was superior to both adalimumab and secukinumab in head-to-head trials. Guselkumab efficacy was also observed in the treatment of psoriasis localized in difficult-to-treat body regions including the scalp, palms and/or soles, and fingernails. Treatment with guselkumab improved health-related quality of life and patient-reported signs and symptoms. Guselkumab has a consistently favourable safety profile and is well tolerated over the long-term. Clinical development of guselkumab as a treatment is ongoing for other immune-mediated inflammatory diseases, including psoriatic arthritis, Crohn's disease, and ulcerative colitis. In the overall management of patients with plaque psoriasis, guselkumab is a robust treatment option with durable maintenance of response over time.
Published: 2021

29. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author: Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Sirna, R., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Savi, E., Stingeni, L., Romano, A., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.
Abstract: Background: Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Objective: To assess dupilumab effectiveness and safety in adults with moderate-to-severe AD in a real-life Italian multicentre retrospective cohort. Methods: Adult moderate-to-severe AD patients, referring to 39 Italian centers, received dupilumab in the context of a national patient access program. Disease assessment was performed at baseline, after 4 and 16 weeks of treatment using Eczema-Area-and-Severity-Index (EASI) score, itch and sleep numerical-rating-score (itch-NRS, sleep-NRS) and Dermatology-Life-Quality-Index (DLQI). Results: A total of 109 (71 M/38F) patients was studied. There was a significant reduction in EASI score, itch-NRS, sleep-NRS and DLQI from baseline to week 4 and a further significant decline to week 16. EASI 50, EASI75 and EASI90 were achieved by 59.6%, 28.4% and 9.3% of patients at 4 weeks and by 87.2%, 60.6% and 32.4% of them at 16 weeks, respectively. Adverse events were experienced by 19.2% (21/109) of the patients and they were all mild in intensity, being conjunctivitis the most common side effect. Conclusions: Dupilumab significantly improved disease severity, pruritus, sleep loss and quality of life with an acceptable safety profile.
Published: 2021

30. Lamotrigine Subacute Cutaneous Lupus Erythematous

Author: Pizzatti L, Rongioletti F, Pilloni L, Atzori L, Pizzatti, L, Rongioletti, F, Pilloni, L, and Atzori, L
Subjects: Drug-induced Sub acute lupus erythematosus, Adverse drug reaction, Lamotrigine, Drug causality assessment
Abstract: Objective: Lamotrigine is a new generation anticonvulsant, also used in bipolar type 1 disorders to prevent occurrence of mood episodes not responding to traditional antidepressant, which is an increasing indication worldwide. Skin adverse events occur in 5-10% of patients, but are usually mild and self-limiting. The occurrence of drug-induced lupus erythematosus is an uncommon, but severe condition, usually requiring discontinuation of the drug. Methods: A spontaneous pharmacovigilance case reporting is presented, following the causality assessment criteria, including temporal association with drug exposure, exclusion of other etiologies, dechallenge and rechallenge. Skin biopsy for normal histopathology and direct immunofluorescence was performed to assess the diagnosis of lupus erythematosus. Results: A 77 years old woman was hospitalized in the Dermatology Clinic of Cagliari University for a lamotrigine Induced Subacute Cutaneous Lupus Erythematosus, confirmed by improvement after drug dismission, and immediate recurrence at re-exposure. The last measure was performed on request of the neurologist with the consent of the patient, because of a high suicidal risk, not responding to traditional antidepressants, and well controlled by lamotrigine. Another peculiarity of our observation is a potential dose-related effects, as the patients was assuming lamotrigine from 2 years, and skin manifestations actually began 3 weeks after the dosage was doubled to 100 mg daily. Conclusion: If confirmed by other observation, drug-induced subacute cutaneous lupus erythematosus might be dose-dependent, and careful clinician’s dosage monitoring might prevent occurrence, preserving the lamotrigine use for the many patients who need it. Dermatologist referral is warrant in front of any suspect cutaneous adverse reaction due to psychotropic medications, to provide prompt recognition, adequate assessment and supportive management of such difficult and delicate patients.
Published: 2019

31. Nivolumab Bullous Pemphigoid: Case Description and Literature Review

Author: ANEDDA, JASMINE ALICE, Atzori L, Pilloni L, Rongioletti F, Anedda, JASMINE ALICE, Atzori, L, Pilloni, L, and Rongioletti, F
Subjects: Nivolumab, Adverse cutaneous reactions, Bullous pemphigoid
Abstract: Nivolumab is a monoclonal antibody, belonging to the checkpoint inhibitors, recently approved for treatment of recurrent or metastatic non-small cell lung cancer, melanoma, and renal cell carcinoma. Although very efficacious, oncologic immunotherapy is associated with a new spectrum of dermatological adverse events, and spontaneous reporting is advisable to define presentation, prognosis and real-life management. In particular, development of bullous pemphigoid (BP), characterized by pathologic autoantibody formation and complement deposition in the skin. is a rare, but severe event, potentially life-threatening, which requires high doses corticosteroids, or even more aggressive immunosuppression. We describe a 73-year-old Caucasian man, under nivolumab therapy for metastatic renal carcinoma, with 2-month-history of a bullous itching eruption on the trunk and arms, rapidly responding to standard corticosteroids treatment and nivolumab dismission, supporting the decision to taper and completely interrupt steroids. Unfortunately, 3 weeks after complete steroidal washout, the itching bullous eruption relapsed, confirming that the autoimmune disease, once aroused by the drug-induced immune unbalance, has a clinical course superimposable to the idiopathic disease. Prompt referral to the dermatologist is advisable in patients under oncologic immunotherapy, developing pruritus and skin eruptions to address the correct diagnostic workup and management.
Published: 2019

32. Acute Generalized Exanthematous Pustulosis with Erythema Multiforme‐Like lesions in a COVID‐19 woman

Author: Robustelli Test, E., Vezzoli, P., Carugno, A., Raponi, F., Gianatti, A., Rongioletti, F., and Sena, P.
Subjects: Drug reaction, COVID‐19, viruses, Acute Generalized Exanthematous Pustulosis (AGEP), virus diseases, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), Letters to Editor, Letter to Editor, Hydroxychloroquine (HCQ), Skin
Abstract: The antimalarials, Chloroquine and Hydroxychloroquine (HCQ), and the antivirals Lopinavir/Ritonavir have been recently recorded as having anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) effects.1 In particular, regarding Italy, one of the countries most affected by the pandemic, the Italian Society of Infectious and Tropical disease (Lombardy section) has recommended the use of HCQ for treatment of coronavirus disease 2019 (COVID‐19).
Published: 2020

33. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis

Author: Scala, E., Megna, M., Amerio, P., Argenziano, G., Babino, G., Bardazzi, F., Bianchi, L., Caldarola, Giacomo, Campanati, A., Cannavo, S. P., Chiricozzi, Andrea, Conti, A., Damiani, G., Dapavo, P., De Simone, C., Esposito, M., Fabbrocini, G., Fargnoli, M. C., Ferrara, F., Fidanza, R., Gualdi, G., Guarneri, C., Hansel, K., Malagoli, P., Malara, G., Micali, G., Mugheddu, C., Musumeci, M. L., Odorici, G., Offidani, A., Pescitelli, L., Prignano, F., Raimondo, A., Ribero, S., Rongioletti, F., Stingeni, L., Trifiro, C., Zanframundo, S., Balato, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Scala, E., Megna, M., Amerio, P., Argenziano, G., Babino, G., Bardazzi, F., Bianchi, L., Caldarola, Giacomo, Campanati, A., Cannavo, S. P., Chiricozzi, Andrea, Conti, A., Damiani, G., Dapavo, P., De Simone, C., Esposito, M., Fabbrocini, G., Fargnoli, M. C., Ferrara, F., Fidanza, R., Gualdi, G., Guarneri, C., Hansel, K., Malagoli, P., Malara, G., Micali, G., Mugheddu, C., Musumeci, M. L., Odorici, G., Offidani, A., Pescitelli, L., Prignano, F., Raimondo, A., Ribero, S., Rongioletti, F., Stingeni, L., Trifiro, C., Zanframundo, S., Balato, A., and Chiricozzi A. (ORCID:0000-0002-6739-0387)
Abstract: Background Knowledge regarding differences in care for psoriatic patients is limited. The aim of this study was to investigate factors influencing prescription of systemic treatments for patients with psoriasis with a special focus on socioeconomic factors. Methods and findings This was a non-interventional, cross-sectional study, conducted in 18 Italian University and/ or hospital centers with psoriasis-specialized units. Questionnaires evaluating demographic and socioeconomic characteristics were administered to participants. Overall, 1880 consecutive patients affected by mild-to-severe psoriasis were recruited. Univariate and multivariable logistic regression analyses of systemic therapy prescription, with a special focus on biologics, accounting for the above mentioned characteristics were performed. Our analysis showed that all analyzed patients' characteristics were significantly associated with biological therapy compared to non-biological systemic one. Particularly, women were less likely to receive biologics than men (OR = 0.66; 95% CI, 0.57-0.77). Elderly patients (≥65 years) and subjects with a BMI ≥30 had lower odds to receive biologics respect to adults (≥35-64 years) (OR = 0.33; 95% CI, 0.25-0.40), and subjects with BMI≥25<30 (OR = 0.64; 95% CI, 0.53-0.77), respectively. Northern and Southern patients were both less likely to receive biologics than Central patients (OR = 0.75; 95% CI, 0.63-0.89, and OR = 0.56; 95% CI,0.47-0.68, respectively). Lower economic profile and never reading books were both associated with decreased odds of receiving biological therapy. Conclusions This study shows that sex, age, comorbidities, and socioeconomic characteristics influence the prescription of systemic treatments in psoriasis, highlighting that there are still unmet needs influencing the therapeutic decision-making process that have to be addressed.
Published: 2020

34. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

Author: Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), De Simone C. (ORCID:0000-0002-0898-0045), Talamonti, M., Galluzzo, M., Chiricozzi, Andrea, Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Belloni Fortina, A., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Venturini, M., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, Ketty, Balestri, R., Bernardini, N., Botti, E., Burlando, M., Caldarola, Giacomo, Cattaneo, A., Dapavo, P., Dastoli, S., De Simone, Clara, Di Nuzzo, S., Diotallevi, F., Fierro, M. T., Fidanza, R., Foti, C., Gambini, D. M., Gambardella, A., Girolomoni, G., Guarneri, C., Gualdi, G., Hansel, C., Megna, M., Mugheddu, C., Musumeci, M. L., Patrizi, A., Pellacani, G., Piaserico, S., Richetta, A. G., Rosi, E., Rossi, M. T., Sacchelli, L., Tiberio, R., Tilotta, G., Trovato, E., Vezzoni, R., Zangrilli, A., Chiricozzi A. (ORCID:0000-0002-6739-0387), Peris K. (ORCID:0000-0002-5237-0463), Caldarola G. (ORCID:0000-0002-8837-9232), and De Simone C. (ORCID:0000-0002-0898-0045)
Abstract: N/A
Published: 2020

35. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study

Author: Patruno, C., Napolitano, M., Argenziano, G., Peris, Ketty, Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, Maria Teresa, Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, Maria Concetta, Ferrillo, M., Galluzzo, M., Gori, Niccolo', Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, Katia Elisabetta, Ravaioli, G. M., Ribero, S., Romanelli, Margherita, Romita, P., Tolino, E., Trifiro, C., Peris K. (ORCID:0000-0002-5237-0463), Iannone M., Fargnoli M. C., Gori N., Provenzano E., Romanelli M., Patruno, C., Napolitano, M., Argenziano, G., Peris, Ketty, Ortoncelli, M., Girolomoni, G., Offidani, A., Ferrucci, S. M., Amoruso, G. F., Rossi, M., Stingeni, L., Malara, G., Grieco, T., Foti, C., Gattoni, M., Loi, C., Iannone, Maria Teresa, Talamonti, M., Stinco, G., Rongioletti, F., Pigatto, P. D., Cristaudo, A., Nettis, E., Corazza, M., Guarneri, F., Amerio, P., Esposito, M., Belloni Fortina, A., Potenza, C., Fabbrocini, G., Angileri, L., Bianchelli, T., Borghi, A., Buligan, C., Calabrese, G., Calzavara Pinton, P., Caroppo, F., Chello, C., Dal Bello, G., Damiani, G., Fargnoli, Maria Concetta, Ferrillo, M., Galluzzo, M., Gori, Niccolo', Gualdi, G., Hansel, K., Macchia, L., Mariano, M., Nistico, S. P., Pertusi, G., Piras, V., Provenzano, Katia Elisabetta, Ravaioli, G. M., Ribero, S., Romanelli, Margherita, Romita, P., Tolino, E., Trifiro, C., Peris K. (ORCID:0000-0002-5237-0463), Iannone M., Fargnoli M. C., Gori N., Provenzano E., and Romanelli M.
Abstract: Background: Treatment of moderate-to-severe atopic dermatitis (AD) in the elderly may be challenging, due to side-effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab are not yet well known. Objectives: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥65 years and affected by severe AD. Their main clinical features were also examined. Methods: Data of elderly patients with severe (EASI ≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS and DLQI) scores at baseline and after 16 weeks of treatment. Results: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis. The coexistence of more than one phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18–64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event. Conclusions: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe tre
Published: 2020

36. Management of cutaneous melanoma: Comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology

Author: Argenziano, G., Brancaccio, G., Moscarella, E., Dika, E., Fargnoli, Maria Concetta, Ferrara, Giovanna, Longo, C., Pellacani, G., Peris, Ketty, Pimpinelli, N., Quaglino, P., Rongioletti, F., Simonacci, Matteo, Zalaudek, Iri, Calzavarapinton, P., Fargnoli M. C., Ferrara G., Peris K. (ORCID:0000-0002-5237-0463), Simonacci M., Zalaudek I., Argenziano, G., Brancaccio, G., Moscarella, E., Dika, E., Fargnoli, Maria Concetta, Ferrara, Giovanna, Longo, C., Pellacani, G., Peris, Ketty, Pimpinelli, N., Quaglino, P., Rongioletti, F., Simonacci, Matteo, Zalaudek, Iri, Calzavarapinton, P., Fargnoli M. C., Ferrara G., Peris K. (ORCID:0000-0002-5237-0463), Simonacci M., and Zalaudek I.
Abstract: The melanoma care landscape is changing fast in the last years. As a result of new insights in melanoma biology, prognosis and therapeutic options, both the American Joint Committee on Cancer (AJCC) and the World Health OrgaÂnization (WHO) Classification of Skin Tumors underwent substantial changes in 2018. Consequently, all the leading guidelines on melanoma management have been updated. Most of the recommendations derive from systematic reÂviews, while others are based on expert opinion, due to the lack of high-level evidence in some aspects of melanoma management. We provide a revision of all the available guidelines that have been updated to the 8th version of the AJCC classification system. Comparison is not provided for topics on which there is agreement on the standard of care.
Published: 2020

37. A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis

Author: Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., Gallo R., Fargnoli, Maria Concetta, Esposito, M., Ferrucci, S., Girolomoni, G., Offidani, A., Patrizi, A., Peris, Ketty, Costanzo, Rosa Maria Alba, Malara, G., Pellacani, G., Romanelli, Margherita, Amerio, P., Cristaudo, A., Flori, M. L., Motolese, A., Betto, P., Patruno, C., Pigatto, P., Peccianti, C., Stinco, G., Zalaudek, Iri, Bianchi, L., Boccaletti, V., Cannavo, S. P., Cusano, F., Lembo, S., Mozzillo, R., Gallo, Rosanna, Potenza, C., Rongioletti, F., Tiberio, R., Grieco, T., Micali, G., Persechino, S., Pettinato, M., Pucci, S., Stingeni, L., Caruso, C., Argenziano, G., Fargnoli M. C., Peris K. (ORCID:0000-0002-5237-0463), Costanzo A., Romanelli M., Zalaudek I., and Gallo R.
Abstract: na
Published: 2020

38. Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore

Author: Marzano, A V, Chiricozzi, Andrea, Giovanardi, Giulia, Argenziano, G, Bettoli, V, Bianchi, L, Dapavo, P, Dini, V, Fabbrocini, G, Micali, G, Offidani, A M, Potenza, C, Prignano, F, Gualberti, G, Saragaglia, V, Rongioletti, F, Chiricozzi, A (ORCID:0000-0002-6739-0387), Giovanardi, G, Marzano, A V, Chiricozzi, Andrea, Giovanardi, Giulia, Argenziano, G, Bettoli, V, Bianchi, L, Dapavo, P, Dini, V, Fabbrocini, G, Micali, G, Offidani, A M, Potenza, C, Prignano, F, Gualberti, G, Saragaglia, V, Rongioletti, F, Chiricozzi, A (ORCID:0000-0002-6739-0387), and Giovanardi, G
Abstract: Background. Hidradenitis suppurativa (HS) is a chronic, debilitating disease with a considerable effect on patient quality of life. Its clinical severity can be measured using different scoring systems; however few of them include patient-centred parameters. Objective. To create a new scoring system for HS that includes a quality-of-life instrument, the HIDRAdisk. Methods. This post-hoc analysis was carried out within the framework of a multicentre, longitudinal, epidemiologic study conducted over 9 months on quality-of-life aspects of HS. The new severity score was created using as reference a question from the Subject Satisfaction Questionnaire (SSQ) concerning the severity of HS as evaluated by the patient. Associated variables were selected using univariable and multivariable logistic regression models. The discriminant capabilities of the final model and of the final score were evaluated by the area under the receiver operating characteristic curve and the Hosmer-Lemeshow test. Results. The study population included 308 patients with HS of any severity grade. According to the results of the regression models, the variables associated with the reference SSQ measure were number of inflammatory nodules, abscesses and draining fistulas; the HIDRAdisk score; and the number of subumbilical lesions. The HIDRAscore is obtained by the sum of the scores associated with the number of these parameters. Possible scores range from 0 to 10. Conclusion. The HIDRAscore is a new scoring system for HS severity which, in addition to the clinical evaluation by the physician, includes a validated patient-reported outcome measure, the HIDRAdisk.
Published: 2020

39. Interobserver reproducibility of histological features in cutaneous malignant melanoma

Author: Urso, C., Rongioletti, F., Innocenzi, D., Saieva, C., Batolo, D., Chimenti, S., Filotico, R., Gianotti, R., Lentini, M., Tomasini, C., Rebora, A., and Pippione, M.
Subjects: Melanoma -- Diagnosis, Health
Published: 2005

40. A Multicenter Study on the Prevalence of Clinical Patterns and Clinical Phenotypes in Adult Atopic Dermatitis

Author: Nettis, E, primary, Ortoncelli, M, additional, Pellacani, G, additional, Foti, C, additional, Di Leo, E, additional, Patruno, C, additional, Rongioletti, F, additional, Argenziano, G, additional, Ferrucci, SM, additional, Macchia, L, additional, Napolitano, M, additional, Ribero, S, additional, Bonzano, L, additional, Romita, P, additional, Di Bona, D, additional, Bennardo, L, additional, Piras, V, additional, Calabrese, G, additional, Tavecchio, S, additional, Detoraki, C, additional, Carbonara, M, additional, and Fabbrocini, G, additional
Published: 2020
Full Text: View/download PDF

41. Histological features used in the diagnosis of melanoma are frequently found in benign melanocytic naevi

Author: Urso, C., Rongioletti, F., Innocenzi, D., Batolo, D., Chimenti, S., Fanti, P. L., Filotico, R., Gianotti, R., Lentini, M., Tomasini, C., and Pippioni, M.
Subjects: Melanoma -- Research, Melanoma -- Diagnosis, Health
Published: 2005

42. Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients

Author: Fabbrocini, G., Marasca, C., Megna, M., Peris, Ketty, Amerio, P., Ardigo, M., Argenziano, G., Berti, Emanuele, Bettoli, V., Bianchi, L., Bongiorno, M. R., Cacciapuoti, S., Calzavara Pinton, P., Cannavo, S. P., Costanzo, Rosa Maria Alba, Cusano, F., Donini, M., Fierro, M. T., Lo Re, M., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Pigatto, P., Pimpinelli, N., Potenza, C., Romanelli, Margherita, Rongioletti, F., Stingeni, L., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Costanzo A., Romanelli M., Fabbrocini, G., Marasca, C., Megna, M., Peris, Ketty, Amerio, P., Ardigo, M., Argenziano, G., Berti, Emanuele, Bettoli, V., Bianchi, L., Bongiorno, M. R., Cacciapuoti, S., Calzavara Pinton, P., Cannavo, S. P., Costanzo, Rosa Maria Alba, Cusano, F., Donini, M., Fierro, M. T., Lo Re, M., Micali, G., Offidani, A., Parodi, A., Patrizi, A., Pellacani, G., Pigatto, P., Pimpinelli, N., Potenza, C., Romanelli, Margherita, Rongioletti, F., Stingeni, L., Peris K. (ORCID:0000-0002-5237-0463), Berti E., Costanzo A., and Romanelli M.
Abstract: Background: Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disease characterized by a significant impairment of patients’ quality of life (QoL). It has been recently found that clinical severity of HS does not correlate well with QoL. Therefore, it is important to enhance the evaluation of severity considering the disease burden on QoL. Recently, a new graphical tool able to better describe HS burden, the so-called HIDRAdisk, has been introduced. Objective: To investigate the utility of HIDRAdisk in clinical practice before and after treatment and to analyse whether specific factors such as age and gender may influence the outcomes in patients with moderate-to-severe HS. Methods: A single-centre retrospective study on 24 patients (13F/11M, mean age 38 ± 15 years) with moderate-to-severe HS was performed. Clinical data (disease severity and quality of life) were collected at baseline and after 12 weeks of adalimumab. Results: HIDRAdisk showed significantly better improvements in males (69.8 ± 6.2–49.6 ± 10.8) compared to females (80.7 ± 6.0–72.3 ± 6.7), P <0.001. A significant correlation was found in the total population between HS severity values measured through the modified Sartorius score (mSS) and QoL measured through HIDRAdisk. As regards the relationship between disease outcomes and age, a trend for better HIDRAdisk outcomes in younger patients (<40 years) compared to older ones was observed. Conclusions: HIDRAdisk appears as a complete and informative tool which can easily measure the global burden of HS, guiding treatment choice and evaluating its efficacy.
Published: 2019

43. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa

Author: Peris, Ketty, Lo Schiavo, A., Fabbrocini, G., Dini, Veronica, Patrizi, A., Fusano, M., Bianchi, L., Guanziroli, Eleonora, Guarneri, C., Parodi, A., Bertoldi, A., Musumeci, M. L., Offidani, A., Rongioletti, F., Pistone, G., Malara, G., Potenza, C., Casari, A., Franchi, C., Ardigo, M., Cusano, F., Stingeni, L., Amerio, P., Mancini, L. L., Prignano, F., Deboli, T., Gualberti, G., Saragaglia, V., Bettoli, V., Peris K. (ORCID:0000-0002-5237-0463), Dini V., Guanziroli E., Peris, Ketty, Lo Schiavo, A., Fabbrocini, G., Dini, Veronica, Patrizi, A., Fusano, M., Bianchi, L., Guanziroli, Eleonora, Guarneri, C., Parodi, A., Bertoldi, A., Musumeci, M. L., Offidani, A., Rongioletti, F., Pistone, G., Malara, G., Potenza, C., Casari, A., Franchi, C., Ardigo, M., Cusano, F., Stingeni, L., Amerio, P., Mancini, L. L., Prignano, F., Deboli, T., Gualberti, G., Saragaglia, V., Bettoli, V., Peris K. (ORCID:0000-0002-5237-0463), Dini V., and Guanziroli E.
Abstract: Background: Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease characterized by painful inflamed nodules, recurrent abscesses and fistulas located in apocrine gland–bearing body sites. The negative impact of HS on patient's quality of life (QoL) has been reported to be greater than other dermatologic conditions as psoriasis and atopic eczema, and its improvement is an important goal in disease management. Nowadays, there are no specific validated QoL instruments available for HS and generic dermatologic questionnaires are used. Objective: The objective of this study was to demonstrate the validity, reliability and responsiveness of HIDRAdisk, a new innovative tool designed for rapid assessment of HS burden and, at the same time, an intuitive graphic visualization of the measurement outcome. Methods: A multicentre, longitudinal, observational study was conducted to validate the HIDRAdisk compared with other validated questionnaires [Skindex-16, Dermatology Life Quality Index (DLQI), Work Productivity and Activity Impairment–General Health (WPAI:GH)] and to evaluate its correlation with disease severity in Italian patients with any degree of HS severity, as measured by Hurley stage and HS Physician Global Assessment (HS-PGA). Results: A total of 140 patients (59% women; mean age 34.9 ± 11.0 years) were enrolled in 27 dermatologic centres. HIDRAdisk showed a strong correlation with Skindex-16 and DLQI, and a good one with WPAI:GH (correlation coefficient: 0.7568, 0.6651 and 0.5947, respectively) and a statistically significant correlation with both Hurley stage and HS-PGA. Very good internal consistency (Cronbach coefficient >0.80; intraclass correlation coefficient >0.6), with correlation between the 10 items, good test–retest reliability (Spearman correlation coefficient, 0.8331; P < 0.0001) and responsiveness to changes were demonstrated. Conclusion: Our study shows that HIDRAdisk, a short and innovativ
Published: 2019

44. Improving the disease awareness: how a communication campaign brings hidradenitis suppurativa to the light

Author: Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., Zalaudek I., Ribero, S., Dapavo, P., Casalegno, C., Alaibac, M., Argenziano, G., Arpaia, N. G., Bagnoni, G., Berti, Emanuele, Bianchi, L., Bianchini, D., Calzavara Pinton, P., Cannavo, S. P., Congedo, Maria Teresa, Corrao, S., Costanzo, Rosa Maria Alba, Cusano, F., Dattola, S., Dattoli, S., Deledda, S., Donini, M., Fabbrocini, G., Teresa Fierro, M., Foti, C., Galluccio, A. G., Gatti, A., Rene Girardelli, C., Girolomoni, G., Lemme, G., Malagoli, P., Malara, G., Mercuri, S. R., Micali, G., Montesu, M. A., Offidani, A., Papini, M., Parodi, A., Patrizi, A., Pellacani, G., Peris, Ketty, Piccirillo, A., Pigatto, P., Pimpinelli, N., Potenza, C., Provenzano, Katia Elisabetta, Romanelli, Margherita, Rongioletti, F., Savoia, P., Simonacci, Matteo, Sirna, R., Stinco, G., Valenti, Gianfranco, Zalaudek, Iris, Berti E., Congedo M., Costanzo A., Peris K. (ORCID:0000-0002-5237-0463), Provenzano E., Romanelli M., Simonacci M., Valenti G., and Zalaudek I.
Abstract: Background: Hidradenitis suppurativa is an inflammatory skin disease that presents a recurrence of painful and suppurating lesions in the apocrine gland-bearing regions, with a strong impact on the patients’ life quality. Despite its peculiar presentation, early forms are often underestimated by patients and this would inevitably result in late diagnosis and delayed therapy. Objectives: Improved communication around the disease could facilitate self-diagnosis and a quicker response from healthcare practitioners, especially in this moment when we dispose of effective treatment against this disease. Methods: A HS awareness campaign was conducted for 2 years with the help of a media agency and a patients’ association. Results: Results confirm that a better communication has a strong impact on the disease awareness. Conclusions: This paper demonstrates that the more this disease awareness is carried on, the more quick, effective and efficient the patient's management could be.
Published: 2019

45. Elderly psoriatic patients under biological therapies: an Italian experience

Author: Ricceri, F., Bardazzi, F., Chiricozzi, Andrea, Dapavo, P., Ferrara, F., Mugheddu, C., Romanelli, M., Rongioletti, F., Prignano, F., Chiricozzi A. (ORCID:0000-0002-6739-0387), Ricceri, F., Bardazzi, F., Chiricozzi, Andrea, Dapavo, P., Ferrara, F., Mugheddu, C., Romanelli, M., Rongioletti, F., Prignano, F., and Chiricozzi A. (ORCID:0000-0002-6739-0387)
Abstract: Background: The number of elderly patients with psoriasis is steadily increasing in the Western world; nevertheless, they are frequently excluded from biological clinical trials and described as a high-risk group for adverse events. Thus, there is lack of information concerning safety and effectiveness of available treatments for psoriasis in the elderly, particularly about new biological systemic drugs. Objective: Our aim was to describe our experience with all biological therapies currently used in the elderly (>65 years) psoriatic patients. Methods: A retrospective multicentric review of clinical records of all psoriatic patient aged 65 years or older actually receiving biological drugs (etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, ustekinumab or secukinumab) was undertaken. Results: Our study population included 266 elderly psoriatic patients actually receiving any biological therapy (adalimumab 31.2%, ustekinumab 28.9%, etanercept 20.3%, secukinumab 15%, infliximab 3%, golimumab 1% and certolizumab pegol 0.6%). The PASI score at the baseline (week 0) ranged from 4 to 54; mean ± SD, 16.5 ± 7.1, which changed after biological administration to 3.7 ± 8 at week 16, 1.6 ± 2.1 at week 28 and 1.2 ± 2.1 at week 52. Among 266 elderly psoriatic patients, 25 adverse events were reported during the observation period. The most frequent events were infections with 12 (48%) reports, followed by malignancies with four (16%) reports. Conclusions: To date, our study represents the widest experience on the use of biological drugs in elderly psoriatic patients. We found that all biologics for psoriasis showed a great efficacy also in elderly people, and the rate and the type of adverse effects were similar to the younger patients. In conclusion, the age alone should not limit our therapeutic options. Further observational study using multiple data sources is needed to evaluate long-term effectiveness and safety for elderly psoriatic patients.
Published: 2019

46. Sporadic progressive mucinous histiocytosis [Histiocytose mucineuse progressive sporadique]

Author: Cascarino M, Caron Y, Butnaru C, Rongioletti F, Fraitag S, Cascarino, M, Caron, Y, Butnaru, C, Rongioletti, F, and Fraitag, S
Subjects: Mucine, Progressive mucinous histiocytosis, Histiocytose mucineuse progressive, Mucin, Non Langerhans’ cell histiocytosis, Histiocytose non langerhansienne
Abstract: Progressive mucinous histiocytosis is a very rare, benign, non-Langerhans' cell histiocytosis limited to the skin. This disorder has been observed solely in women, with the exception of three cases in male patients, and most cases are hereditary. The hereditary forms begin in childhood, with sporadic cases occurring later, and it is characterized by numerous papules of slow progression. The aetiology and mode of genetic transmission remain unclear. We report one sporadic case of progressive mucinous histiocytosis.
Published: 2017

47. Disfiguring Leukoderma Caused by Banned Cosmetics: A Quiz

Author: Atzori, L, primary, Zanniello, R, additional, Sarais, G, additional, Piras, V, additional, Pilloni, L, additional, Zucca, M, additional, Brundu, M, additional, and Rongioletti, F, additional
Published: 2018
Full Text: View/download PDF

48. European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

Author: Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., Krieg, T., Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., and Krieg, T.
Abstract: The term 'sclerosing diseases of the skin' comprises specific dermatological entities, which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first-and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 1 of this guideline provides clinicians with an overview of the diagnosis and treatment of localized scleroderma (morphea), and systemic sclerosis including overlap syndromes of systemic sclerosis with diseases of the rheumatological spectrum.
Published: 2017

49. European dermatology forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

Author: Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., Krieg, T., Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C. P., Rudnicka, L., Frasin, L. A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Olesen, A. Braae, Foeldvari, I., Frances, C., Jalili, A., Just, U., Kahari, V., Karpati, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J. M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkoetter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N. J., and Krieg, T.
Abstract: The term sclerosing diseases of the skin' comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first- and advanced-line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).
Published: 2017

50. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

Author: Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Costanzo, Rosa Maria Alba, Conti, A., Dapavo, P., De Simone, Clara, Foti, C., Naldi, L., Offidani, A., Parodi, A., Piaserico, S., Prignano, F., Rongioletti, F., Stingeni, L., Talamonti, M., Girolomoni, G., Chiricozzi, A. (ORCID:0000-0002-6739-0387), De Simone, C. (ORCID:0000-0002-0898-0045), Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Costanzo, Rosa Maria Alba, Conti, A., Dapavo, P., De Simone, Clara, Foti, C., Naldi, L., Offidani, A., Parodi, A., Piaserico, S., Prignano, F., Rongioletti, F., Stingeni, L., Talamonti, M., Girolomoni, G., Chiricozzi, A. (ORCID:0000-0002-6739-0387), and De Simone, C. (ORCID:0000-0002-0898-0045)
Abstract: Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.
Published: 2017

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

451 results on '"Rongioletti, F"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources